Signaling Pathways Controlling Pluripotency and Early Cell Fate Decisions of Human Induced Pluripotent Stem Cells§

Authors


  • Author contributions: L.V.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing; T.T.: collection and/or assembly of data, data analysis and interpretation; S.B.: collection and/or assembly of data, data analysis and interpretation; C.C.: collection and/or assembly of data, data analysis and interpretation; B.B.: collection and/or assembly of data, provision of study material; M.A.: technical support; J.C.: collection and/or assembly of data; L.Ä.-R.: data analysis and interpretation; S.C.: provision of study material; A.W.: provision of study material; R.A.P.: data analysis and interpretation, manuscript writing.

  • Disclosure of potential conflicts of interest is found at the end of this article.

  • §

    First published online in STEM CELLS EXPRESS 2009.

Abstract

Human pluripotent stem cells from embryonic origins and those generated from reprogrammed somatic cells share many characteristics, including indefinite proliferation and a sustained capacity to differentiate into a wide variety of cell types. However, it remains to be demonstrated whether both cell types rely on similar mechanisms to maintain their pluripotent status and to control their differentiation. Any differences in such mechanisms would suggest that reprogramming of fibroblasts to generate induced pluripotent stem cells (iPSCs) results in novel states of pluripotency. In that event, current methods for expanding and differentiating human embryonic stem cells (ESCs) might not be directly applicable to human iPSCs. However, we show here that human iPSCs rely on activin/nodal signaling to control Nanog expression and thereby maintain pluripotency, thus revealing their mechanistic similarity to human ESCs. We also show that growth factors necessary and sufficient for achieving specification of human ESCs into extraembryonic tissues, neuroectoderm, and mesendoderm also drive differentiation of human iPSCs into the same tissues. Importantly, these experiments were performed in fully chemically defined medium devoid of factors that could obscure analysis of developmental mechanisms or render the resulting tissues incompatible with future clinical applications. Together these data reveal that human iPSCs rely on mechanisms similar to human ESCs to maintain their pluripotency and to control their differentiation, showing that these pluripotent cell types are functionally equivalent. STEM CELLS 2009;27:2655–2666

Ancillary